Artelo Biosciences launches underwritten public offering

Artelo Biosciences Inc. (NASDAQ: ARTL) announced September 29 that it has commenced an underwritten public offering of common stock and pre-funded warrants. The clinical-stage pharmaceutical company focuses on developing treatments for cancer, pain, dermatologic and neurological conditions through lipid-signaling pathway modulation.

All securities in the offering will be sold by the company. R.F. Lafferty & Co., Inc. serves as the sole book-running manager for the transaction.

The company stated that completion of the offering depends on market conditions, with no assurance regarding timing, size or final terms. The securities are being offered under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission and became effective July 14, 2023.

A prospectus supplement detailing the offering terms will be filed with the SEC as part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus will be available through the SEC's website and from R.F. Lafferty & Co., Inc.

The company develops proprietary therapeutics targeting lipid-signaling pathways with a pipeline addressing anorexia, cancer, anxiety, dermatologic conditions, pain and inflammation. Artelo is based in Solana Beach, California.

You May Also Be Interested In

• Aveanna selling stockholders launch 15M share secondary offering
• VirTra wins $1.5M Army contract for firearms training in Tajikistan
• QNB Corp. prices stock offering at $42 per share on Nasdaq